OmniAb, Inc. (NASDAQ:OABI – Get Free Report) has been assigned an average rating of “Buy” from the nine research firms that are presently covering the company, Marketbeat.com reports. Nine investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $10.00.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of OmniAb in a research note on Friday, August 11th.
Institutional Investors Weigh In On OmniAb
A number of hedge funds and other institutional investors have recently bought and sold shares of OABI. California State Teachers Retirement System acquired a new position in shares of OmniAb during the first quarter worth $384,000. Bank of New York Mellon Corp acquired a new position in OmniAb during the 1st quarter valued at about $1,341,000. GW&K Investment Management LLC purchased a new stake in OmniAb in the first quarter valued at about $543,000. Tower Research Capital LLC TRC acquired a new stake in OmniAb in the first quarter worth about $93,000. Finally, Kornitzer Capital Management Inc. KS acquired a new position in shares of OmniAb during the first quarter valued at about $6,478,000. Hedge funds and other institutional investors own 58.73% of the company’s stock.
OmniAb Stock Performance
Shares of NASDAQ OABI opened at $5.83 on Tuesday. OmniAb has a fifty-two week low of $1.91 and a fifty-two week high of $10.50. The company has a market cap of $677.27 million, a price-to-earnings ratio of -25.35 and a beta of -0.55. The business’s 50 day moving average price is $5.32 and its 200-day moving average price is $4.38.
OmniAb (NASDAQ:OABI – Get Free Report) last announced its quarterly earnings data on Thursday, August 10th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.04). The business had revenue of $6.95 million during the quarter, compared to the consensus estimate of $13.05 million. Sell-side analysts predict that OmniAb will post -0.45 earnings per share for the current year.
OmniAb Company Profile
OmniAb, Inc, a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.
- Five stocks we like better than OmniAb
- Airline Stocks – Top Airline Stocks to Buy Now
- MarketBeat Week in Review – 8/28 – 9/1
- What Makes a Stock a Good Dividend Stock?
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- How to Invest in Growth Stocks
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.